Float Short %

14.64

Margin Of Safety %

Put/Call OI Ratio

1.32

EPS Next Q Diff

0.2

EPS Last/This Y

1.66

EPS This/Next Y

2.79

Price

66.55

Target Price

92.56

Analyst Recom

1.11

Performance Q

-13.46

Upside

-205.6%

Beta

0.58

Ticker: TARS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	TARS	68.25	0.59	0.20	3925
2026-01-26	TARS	67.89	0.59	0.03	3933
2026-01-27	TARS	68.08	0.59	0.18	3940
2026-01-28	TARS	64.19	0.58	5.33	3970
2026-01-29	TARS	65.72	0.58	0.58	3981
2026-01-30	TARS	64.6	0.58	0.06	3974
2026-02-02	TARS	65.89	0.58	0.15	3989
2026-02-03	TARS	66.81	0.57	0.06	4011
2026-02-04	TARS	63.56	0.58	1.33	4000
2026-02-05	TARS	61.92	0.58	1.00	4003
2026-02-06	TARS	64.66	0.58	0.03	4003
2026-02-09	TARS	65.43	0.57	1.33	4032
2026-02-10	TARS	65.91	0.57	1.00	4036
2026-02-11	TARS	65.33	0.57	1.00	4036
2026-02-12	TARS	63.35	0.57	0.00	4036
2026-02-13	TARS	60.7	0.57	999.99	4068
2026-02-17	TARS	62.74	0.57	0.00	4068
2026-02-18	TARS	63.33	0.55	0.25	4120
2026-02-20	TARS	66.57	1.32	0.01	6154
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	TARS	68.29	99.4	-	-1.41
2026-01-26	TARS	67.88	102.7	-	-1.41
2026-01-27	TARS	68.13	101.8	-	-1.41
2026-01-28	TARS	64.13	101.8	-	-1.41
2026-01-29	TARS	65.74	101.8	-	-1.41
2026-01-30	TARS	64.55	101.8	-	-1.41
2026-02-02	TARS	65.95	101.8	-	-1.41
2026-02-03	TARS	66.81	101.8	-	-1.41
2026-02-04	TARS	63.54	101.8	-	-1.41
2026-02-05	TARS	62.01	101.8	-	-1.41
2026-02-06	TARS	64.65	101.8	-	-1.41
2026-02-09	TARS	65.49	101.8	-	-1.41
2026-02-10	TARS	65.96	101.8	-	-1.41
2026-02-11	TARS	65.29	101.8	-	-1.41
2026-02-12	TARS	63.36	101.8	-	-1.41
2026-02-13	TARS	60.69	101.8	-	-1.41
2026-02-17	TARS	62.79	101.8	-	-1.41
2026-02-18	TARS	63.20	101.8	-	-1.41
2026-02-19	TARS	65.61	101.8	-	-1.41
2026-02-20	TARS	66.55	101.8	-	-1.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	TARS	-2.76	-4.48	11.62
2026-01-26	TARS	-2.76	-5.50	11.62
2026-01-27	TARS	-2.76	-5.50	11.62
2026-01-28	TARS	-2.76	-5.50	13.70
2026-01-29	TARS	-2.76	-5.50	13.70
2026-01-30	TARS	-2.76	-5.50	13.70
2026-02-02	TARS	-2.76	-5.49	13.70
2026-02-03	TARS	-2.76	-5.49	13.70
2026-02-04	TARS	-2.76	-5.49	13.70
2026-02-05	TARS	-2.76	-5.49	13.70
2026-02-06	TARS	-2.76	-5.49	13.70
2026-02-10	TARS	-2.76	-6.52	13.70
2026-02-11	TARS	-2.76	-6.52	14.84
2026-02-12	TARS	-2.76	-6.52	14.84
2026-02-13	TARS	-2.76	-6.52	14.84
2026-02-17	TARS	-2.59	-4.67	14.84
2026-02-18	TARS	-2.59	-4.67	14.84
2026-02-19	TARS	-3.07	-4.67	14.64
2026-02-20	TARS	-3.07	-4.67	14.64
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

-0.1

Insider Transactions

-3.07

Institutional Transactions

-4.67

Beta

0.58

Average Sales Estimate Current Quarter

143

Average Sales Estimate Next Quarter

148

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

21.9

Max Drawdown 5-Year %

-72.4

Target Price

92.56

P/E

Forward P/E

40.89

PEG

P/S

7.72

P/B

8.44

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y

-1.41

EPS Next Y. (Est.)

1.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-22.17

Relative Volume

1.6

Return on Equity vs Sector %

-53.2

Return on Equity vs Industry %

-35.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TARS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y